Insider Selling: Alpha Tau Medical (NASDAQ:DRTS) CFO Sells 32,500 Shares of Stock

Posted by Brian Himes on Jun 4th, 2026

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) CFO Raphi Levy sold 32,500 shares of Alpha Tau Medical stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the transaction, the chief financial officer directly owned 147,680 shares in the company, valued at $1,599,374.40. This represents a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Alpha Tau Medical Price Performance

Shares of Alpha Tau Medical stock traded down $0.32 during trading hours on Thursday, hitting $10.26. The company’s stock had a trading volume of 1,152,083 shares, compared to its average volume of 537,906. The company has a market cap of $926.79 million, a PE ratio of -15.33 and a beta of 1.19. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The business has a 50 day moving average price of $8.48 and a two-hundred day moving average price of $6.92. Alpha Tau Medical Ltd. has a 12-month low of $2.81 and a 12-month high of $11.62.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts expect that Alpha Tau Medical Ltd. will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently modified their holdings of DRTS. Mariner LLC raised its stake in shares of Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after acquiring an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC purchased a new position in Alpha Tau Medical during the 4th quarter worth $48,000. Levin Capital Strategies L.P. increased its holdings in Alpha Tau Medical by 6.3% during the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after purchasing an additional 12,200 shares during the period. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical during the 3rd quarter valued at $62,000. Finally, Wells Fargo & Company MN raised its position in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

DRTS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Alpha Tau Medical in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. LADENBURG THALM/SH SH increased their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Piper Sandler lifted their price objective on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Finally, Citigroup upped their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $12.60.

Check Out Our Latest Report on DRTS

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.